Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, on Monday published Issue 198 of its “Global Fund Observer.” The issue features a summary of a paper submitted by the Global Fund Secretariat to the Strategy, Investment and Impact Committee (SIIC) of the Global Fund Board that contains options and recommendations for the design of its new funding model. The SIIC will discuss the paper at a meeting in Geneva later this month, the GFO states, noting Aidspan provides summaries of each part of the paper on its Discussion Page and invites public comment (10/15).
U.S. Global AIDS Coordinator Ambassador Eric Goosby is “expected to announce a new initiative between the U.S. government, the Rwandan Ministry of Health and 14 American medical schools at a press conference Monday in Kigali, Rwanda,” the New York Times reports. “The Human Resources for Health program will send 100 faculty members from eight medical colleges, five nursing and midwifery schools, and one health management school to Kigali where they will train health professionals and medical students, according to a statement from the Clinton Global Initiative,” the newspaper writes. “The two governments, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the universities have committed $152 million to the seven-year program,” the newspaper notes (Lau, 10/14).
In the Center for Global Development’s (CGD) “Global Health Policy” blog, Amanda Glassman, director of global health policy and a senior fellow at CGD, introduces the center’s new online forum in which they “have asked prominent thinkers and practitioners what reforms the Global Fund should prioritize and how it should best fulfill its mandate of improving the way development aid is managed in addition to advancing the fight against the three diseases as its Board considers new policies and its new Executive Director prepares to takes office.” She continues, “Our initial posts come from Erin Hohlfelder (Policy Director, Global Health at ONE), Anders Nordstrom (Ambassador for Global Health at the Swedish Ministry for Foreign Affairs), and Prashant Yadav (Director of Healthcare Research at the William Davidson Institute, University of Michigan). We will continue to add new perspectives in the coming weeks, so keep an eye out on the Global Health Policy Blog and the forum’s homepage for updates” (10/15).
“Health workers in Myanmar are confident that efforts to narrow the country’s huge gap between access to, and need for, life-saving medicines to treat HIV/AIDS are back on track after the Global Fund to Fight AIDS, Tuberculosis and Malaria invited the country to apply for additional funding,” IRIN reports. “The agency’s coordinator for Myanmar, Eamonn Murphy, said new funds will allow the country to close a ‘treatment gap’ where only one-third of the 120,000 people nationwide who need [antiretrovirals (ARVs)] receive them,” the news service notes. “A spokesman for the Global Fund said it ‘had encouraged an application by the country for more money’ following an August visit to Myanmar by its general director,” IRIN writes. “Health officials drafted a ‘concept note’ outlining how additional funding might be used, which will be reviewed by the Global Fund’s board, Murphy said,” according to the news service, which notes, “It offers two scenarios: the first ensures 85 percent of those who need ARVs receive them by 2015; while with the second, 76 percent of people would be covered, he said.” The news service adds, “Based on feedback from the board, the government will choose a strategy for the proposal to be submitted early next year” (10/12).
“The Global Fund to Fight AIDS, Tuberculosis and Malaria signed a grant agreement worth $102 million with the Churches Health Association of Zambia [CHAZ] Wednesday,” Devex’s “Development Newswire” reports. Part of the grant — $44 million — is “‘old money’ that had already been approved before,'” Marcela Rojo, Global Fund communications officer, told Devex in an email, the news service states, adding, “The money is on top of the $141.8 million in Global Fund grants that the U.N. Development Programme signed on behalf of the health ministry in 2011” (Ravelo, 10/11). “Activities implemented by this grant will focus on prevention of mother-to-child transmission of HIV, promoting male circumcision, expanding and sustaining HIV treatment, reducing new infections, and maintaining a high coverage of impact mitigation,” as well as strengthening counseling and testing and HIV treatment adherence, PANA/Afriquejet notes (10/11).
Fareed Abdullah, CEO of the South African National AIDS Council (SANAC), who took office in July, spoke with PlusNews regarding the body’s reform, the revival of provincial AIDS councils, resource mobilization, and the appointment of a new board that allows SANAC to operate independently. According to the news service, Abdullah said the secretariat has three times as many staff as it did three months ago, adding, “We have a team of eight people working on the grant renewal process for about five Global Fund [to Fight AIDS, Tuberculosis and Malaria] grants. We’ve committed two staff members to dealing with PEPFAR [the U.S.-based President's Emergency Plan for AIDS Relief] and the new agreement to co-manage programs, and we’ll expand [staff] as the needs expand” (10/11).
Inter Press Service examines how Mexico’s government and non-governmental organizations are working to stem the spread of HIV among people who use injection drugs. “According to a project financed by the Global Fund to Fight AIDS, Tuberculosis and Malaria since 2011, the prevalence of HIV/AIDS in Mexico is 5.77 percent among intravenous drug users … compared to 0.24 to 0.3 percent in the general population aged 15 to 49,” IPS writes, noting HIV prevalence among drug users is highest in “northern Mexico, one of the areas in the country hit hardest by drug trafficking.” The news service adds “[t]here are 28 syringe exchange programs in this country of 112 million people, insufficient to serve the entire population of intravenous drug users.” IPS discusses funding shortfalls for syringe exchange programs, legal hurdles to obtaining clean injection equipment, and how the government aims to continue receiving Global Fund money through 2013 (Godoy, 10/11).
Differing Opinions About AMFm 'Unlikely To Be Resolved' After Global Fund Decision On Program's Future
In her “Global Health Blog,” Guardian health editor Sarah Boseley examines the Affordable Medicines Facility-malaria (AMFm), “which aims to enable countries to increase the provision of affordable artemisinin combination therapies (ACTs) through not only the public sector but also the private sector and [non-governmental organizations (NGOs)].” Following pilot projects in seven African countries and an independent evaluation by the London School of Hygiene and Tropical Medicine, the Global Fund to Fight AIDS, Tuberculosis and Malaria, which hosts AMFm, is set to decide the future of the scheme at a board meeting in November. She notes Oxfam recently released a report criticizing the mechanism, saying the evaluation was flawed because it looked at the number of ACTs sold and not lives saved.
The Associated Press examines access to antiretroviral treatment in Myanmar, which “ranks among the world’s hardest places to get HIV care, and health experts warn it will take years to prop up a broken health system hobbled by decades of neglect.” The country, also known as Burma, has been hindered by decades of rule by a military junta and economic sanctions imposed by developed countries, including the U.S., the AP notes, and writes, “Of the estimated 240,000 people living with HIV [in the country], half are going without treatment.” However, “as Myanmar wows the world with its reforms, the U.S. and other nations are easing sanctions,” the news agency writes, adding, “The Global Fund [to Fight AIDS, Tuberculosis and Malaria] recently urged Myanmar to apply for more assistance that would make up the shortfall and open the door for HIV drugs to reach more than 75 percent of those in need by the end of 2015,” as well as medications to fight tuberculosis (TB). The AP details one man’s efforts to obtain antiretrovirals, which are reserved for patients with CD4 cell counts below 150 cells, versus the WHO recommended 350 (Mason, 10/22).
In the last of a series of posts on the U.K. Department for International Development’s (DfID) blog examining the department’s work in Malawi, Neil Squires, DfID head of profession for health, looks at the sustainability of the country’s HIV/AIDS program. “Malawi’s success in increasing access to antiretroviral drugs for HIV is highly dependent on donor funding for medicines,” he writes, adding, “Malawi has to actively consider its resource allocation in order to maximize the benefits and the health gained from the limited resources available.” He notes a report commissioned by UNAIDS on Malawi concluded that “unless Malawi can reduce the incidence of new infections, the scale up in access to antiretroviral drugs will not be sustainable in the medium to long term.” He concludes, “This is an important issue for the Government of Malawi, but also for the key donors who have supported the massive scale up in access to drugs, particularly the Global Fund. Malawi will need to maintain high levels of funding from the Global Fund if it is to maintain its supply of antiretroviral drugs” (10/23).